# W. Eiermann

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/w-eiermann/

## Facts

| Field | Value |
| --- | --- |
| Citations | 44,943 |
| Field | Breast Cancer Treatment Studies |
| h-index | 69 |
| i10-index | 149 |
| OpenAlex ID | https://openalex.org/A5002412211 |
| Works | 450 |

## Researcher papers

Showing 12 of 16.

- [Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2](https://scholariq.org/papers/use-of-chemotherapy-plus-a-monoclonal-antibody-against-her2-for-metastatic/)
- [Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis](https://scholariq.org/papers/pathological-complete-response-and-long-term-clinical-benefit-in-breast-cancer/)
- [Adjuvant Trastuzumab in HER2-Positive Breast Cancer](https://scholariq.org/papers/adjuvant-trastuzumab-in-her2-positive-breast-cancer/)
- [Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes](https://scholariq.org/papers/definition-and-impact-of-pathologic-complete-response-on-prognosis-after/)
- [Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation](https://scholariq.org/papers/talazoparib-in-patients-with-advanced-breast-cancer-and-a-germline-i-brca-i/)
- [Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort](https://scholariq.org/papers/neoadjuvant-chemotherapy-with-trastuzumab-followed-by-adjuvant-trastuzumab/)
- [Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial](https://scholariq.org/papers/risk-adapted-targeted-intraoperative-radiotherapy-versus-whole-breast/)
- [Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial](https://scholariq.org/papers/targeted-intraoperative-radiotherapy-versus-whole-breast-radiotherapy-for-breast/)
- [Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update](https://scholariq.org/papers/recommendations-from-an-international-expert-panel-on-the-use-of-neoadjuvant/)
- [Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study](https://scholariq.org/papers/preoperative-treatment-of-postmenopausal-breast-cancer-patients-with-letrozole-a/)
- [Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer](https://scholariq.org/papers/phase-ii-study-of-temsirolimus-cci-779-a-novel-inhibitor-of-mtor-in-heavily/)
- [Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial](https://scholariq.org/papers/long-term-survival-and-local-control-outcomes-from-single-dose-targeted/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.